Jupiter Neurosciences, Inc. (JUNS:NASDAQ) closed at $3.09 on October 15, 2026, down 3.13% on the day. The stock trades 97.7% below its 52-week high of $135.75 and 37.3% above its 52-week low of $2.25. Jupiter Neurosciences, Inc. is part of the Health Care sector.
| 5D | 1M | 3M | 6M |
|---|---|---|---|
| +4.93% | +5.98% | -75.41% | -90.75% |
In 251 trading sessions since October 14, 2025, JUNS closed higher on 98 days (39%). Its best day was May 21, 2026 (+32.20%) and its worst was May 20, 2026 (-35.94%). The stock moved 10% or more in a single session 37 times. It opened at least 5% above the previous day's high 6 times.
Jupiter Neurosciences is a clinical stage research and development pharmaceutical company. The Company has developed a unique resveratrol platform product targeting treatment of neuro-inflammation. The product, called JOTROL¿ , has many potential indications of use for rare diseases, which of we primarily are targeting Mucopolysaccharidoses Type 1, Friedreichs Ataxia, and MELAS as well as ALS which is in an early development stage. In the larger disease areas, we are primarily targeting Mild Cognitive Impairment/early Alzheimers disease with TBI/concussions and Covid-19 in early development stages. Based on available scientific literature, we believe that JOTROL¿ is the first and only resveratrol product in the world that delivers a therapeutically effective dose of resveratrol in the blood stream without causing gastrointestinal side effects.
Find more stocks like JUNS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.